Dr. Reddys Laboratories Ltd.

Dr. Reddy’s Laboratories is currently trading at Rs. 3724.30, up by 45.85 points or 1.25% from its previous closing of Rs. 3678.45 on the BSE.

The scrip opened at Rs. 3681.00 and has touched a high and low of Rs. 3724.20 and Rs. 3669.10 respectively. So far 3,876 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3732.55 on 08-Apr-2015 and a 52 week low of Rs. 2250.00 on 19-May-2014.

Last one week high and low of the scrip stood at Rs. 3732.55 and Rs. 3530.00 respectively. The current market cap of the company is Rs. 63,568.00 crore.

The promoters holding in the company stood at 25.49% while Institutions and Non-Institutions held 44.19% and 12.91% respectively.

Dr. Reddy’s Laboratories’ and its subsidiary, Promius Pharma, LLC has filed three New Drug Applications (NDAs) with the US Food and Drug Administration (USFDA). The three NDAs are in support of Dr. Reddy’s Proprietary Products group, focused on developing and commercializing therapies in dermatology and neurology.

Of the three, two are related to dermatology (skincare) applications and one is a corticosteroid. The products upon approval will be commercialized by Promius Pharma.

Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.